ACTICOR BIOTECH DISCLOSURECurrent Reports (8-K / ad hoc)

Inside Information / Other news releases

1 Paris, France, January 6, 2025 – 08:00 AM CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the Paris Commercial Court, has declared on January 2, the company in liquidation proceedings. The liquidator is Marc-Antoine Rey, SELARL BDR & Associés, 34 rue Sainte Anne, 75001 Paris, [email protected] In view of this decision by the Paris Commercial Court, Acticor Biotech shares will not be listed again, and Euronext will shortly be asked to delist them. Dr Gilles Avenard has published a letter to shareholders available on the Company’s website: www.acticor-biotech.com About ACTICOR BIOTECH ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 from the work of INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the GPVI platelet receptor for the treatment of cardiovascular emergencies and acute thrombotic diseases. The main clinical indication evaluated is acute ischemic stroke, due to the strong need for safer treatments, particularly those that do not increase the risk of bleeding, and its high incidence. In three international clinical trials involving over 600 stroke patients, no significant impact on neurological improvement (mRS score at 3 months) was demonstrated, with the exception of a sub-population of patients with intracerebral haemorrhage, where mortality was significantly reduced by a factor of 3 (p=0.035) (Mazighi et al. 2024). LIBERATE, a Phase 2 clinical trial in the acute phase of myocardial infarction (STEMI), is currently In progress through an academic partnership with the University of Birmingham (UK). This study aims to demonstrate the efficacy of glenzocimab in reducing the size of myocardial infarction, a critical factor for long-term cardiac function. In all, more than 800 subjects were included in the clinical trials, over 400 of whom were exposed to glenzocimab without safety concerns. The use of glenzocimab in thrombotic diseases is covered by 3 patent families, with an expiry date in 2036 for the first family. For further information, visit: www.acticor-biotech.com Contacts ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder [email protected] Sophie BINAY